Author:
Yu Wenjuan,Mao Liping,Qian Jiejing,Qian Wenbin,Meng Haitao,Mai Wenyuan,Tong Hongyan,Tong Yin,Jin Jie
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference35 articles.
1. Kell J (2006) Treatment of relapsed acute myeloid leukaemia. Rev Recent Clin Trials 1:103–111
2. Rowe JM, Li X, Cassileth PA, Appelbaum FR, Schiffer CA, Wiernik PH, Litzow MR, Cripe LD, Lazarus HM, Paietta E, Dewald GW, Weinstein HJ, Ogden AK, Woods WG, Shep-herd L, Feusner JH, Bloomfield CD, Tallman MS (2005) Very poor survival of patients with AML who relapse after achieving a first complete remission: the Eastern Cooperative Oncology Group Experience (Abstract 546). Blood 106:162a
3. Vogler WR, McCarley DL, Stagg M, Bartolucci AA, Moore J, Martelo O, Omura GA (1994) A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia 8:1847–1853
4. Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Wörmann B, Büchner T, Hiddemann W (1998) Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 12:1049–1055
5. Karanes C, Kopecky KJ, Head DR, Grever MR, Hynes HE, Kraut EH, Vial RH, Lichtin A, Nand S, Samlowski WE, Appelbaum FR (1999) A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leuk Res 23:787–794
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献